Chart, page-2514

We have a lot of shares on issue and a large free float (remember we did a 1 for 10 consolidation not long ago), so we aren't going to do a moonshot you would think, more of a grinding rally higher that we've seen all year and 25 cents is enormous resistance I'm sure you can all see. So my strategy is to buy on dips below 20 cents and not chase.

Although I do recognize that the failure of Sarepta and by default Bio-sciences similar gene treatment for DMD does open up our novel gene approach attacking the inflammation not the disease (have I got that right?) to unexpected new commercial interest